このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Compugen マネジメント
マネジメント 基準チェック /34
Compugen'sの CEO はAnat Cohen-Dayagで、 Jun2009年に任命され、 の在任期間は 10.33年です。 の年間総報酬は$ 1.46Mで、 32.7%給与と67.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.063%を直接所有しており、その価値は$ 109.99K 。経営陣と取締役会の平均在任期間はそれぞれ4.6年と7年です。
主要情報
Anat Cohen-Dayag
最高経営責任者
US$1.5m
報酬総額
| CEO給与比率 | 32.7% |
| CEO在任期間 | 15yrs |
| CEOの所有権 | 0.06% |
| 経営陣の平均在職期間 | 4.6yrs |
| 取締役会の平均在任期間 | 7yrs |
経営陣の近況
Recent updates
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report
May 22
Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge
May 01Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?
Apr 05Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Mar 08Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans
Feb 17Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
Oct 10Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?
Jun 22Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 04Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Sep 21Compugen appoints Alberto Sessa as CFO
Sep 12Compugen gets Japanese patent for COM701, anti-PVRIG antibodies
Aug 24Compugen Q2 2022 Earnings Preview
Aug 03Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Jun 23Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Mar 02Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 04Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation
Aug 27Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth
Jun 28Compugen gains on takeover speculation after iTeos Therapeutics deal
Jun 14Compugen reports updated COM701 data from Phase 1 study at ASCO21
Jun 08Compugen's COM902 demonstrates potential benefit in cancer
Apr 27Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 15Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?
Feb 08
A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)
Jan 04Compugen earns $2M milestone under antibody development deal with AstraZeneca
Dec 23Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 30Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Compugen: Speculative Play For Immuno-Oncology Exposure
Nov 07Compugen Q3 Earnings Preview
Nov 04CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$17m |
| Dec 31 2023 | US$1m | US$479k | -US$19m |
| Sep 30 2023 | n/a | n/a | -US$32m |
| Jun 30 2023 | n/a | n/a | -US$33m |
| Mar 31 2023 | n/a | n/a | -US$33m |
| Dec 31 2022 | US$1m | US$479k | -US$34m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$34m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$1m | US$498k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$34m |
| Jun 30 2021 | n/a | n/a | -US$36m |
| Mar 31 2021 | n/a | n/a | -US$32m |
| Dec 31 2020 | US$1m | US$453k | -US$30m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | US$941k | US$395k | -US$27m |
| Sep 30 2019 | n/a | n/a | -US$30m |
| Jun 30 2019 | n/a | n/a | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$31m |
| Dec 31 2018 | US$854k | US$391k | -US$23m |
| Sep 30 2018 | n/a | n/a | -US$23m |
| Jun 30 2018 | n/a | n/a | -US$29m |
| Mar 31 2018 | n/a | n/a | -US$28m |
| Dec 31 2017 | US$740k | US$392k | -US$37m |
報酬と市場: Anatの 総報酬 ($USD 1.46M ) は、 US市場 ($USD 1.58M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Anatの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Anat Cohen-Dayag (57 yo)
15yrs
在職期間
US$1,464,448
報酬
Dr. Anat Cohen-Dayag, Ph D., served as an Independent Director at Gamida Cell Ltd since January 28, 2022 until March 2023. She serves as Director at has been Chief Executive Officer and President at Compug...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 15yrs | US$1.46m | 0.063% $ 98.8k | |
| Chief Scientific Officer | 4.3yrs | US$540.64k | データなし | |
| Senior Vice President of Technology Innovation | 6.4yrs | US$532.26k | データなし | |
| Vice President of Preclinical Development | 3.2yrs | US$570.40k | データなし | |
| Chief Financial Officer | 1.6yrs | データなし | データなし | |
| Head of Investor Relations & Corporate Communications | no data | データなし | データなし | |
| General Counsel & Corporate Secretary | 5.4yrs | データなし | データなし | |
| Vice President of Human Resources | 17.4yrs | データなし | データなし | |
| Senior VP & Senior Advisor of Data and Informatics Solutions | 4.6yrs | データなし | データなし | |
| Vice President Research and Discovery | no data | データなし | データなし | |
| Chief Medical Officer | less than a year | データなし | データなし |
4.6yrs
平均在職期間
56yo
平均年齢
経験豊富な経営陣: CGENの経営陣は 経験豊富 であると考えられます ( 4.6年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 10.3yrs | US$1.46m | 0.063% $ 98.8k | |
| Member of Scientific Advisory Board | 3.8yrs | データなし | データなし | |
| Independent Director | 6yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 10.8yrs | データなし | データなし | |
| Independent Director | 6yrs | データなし | データなし | |
| Independent Chairman of the Board | 6.7yrs | データなし | データなし | |
| Independent Director | 6yrs | データなし | データなし | |
| Chairman of Scientific Advisory Board | 10.4yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 10.8yrs | データなし | データなし | |
| Independent Director | 4.9yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 10.8yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 7.3yrs | データなし | データなし |
7.0yrs
平均在職期間
58yo
平均年齢
経験豊富なボード: CGENの 取締役会 は 経験豊富 であると考えられます ( 7年の平均在任期間)。